Is Precipio, Inc. (NASDAQ:PRPO) a buy in 2026?
Hold. Precipio, Inc. is a wait-and-watch at today's price, not a fresh buy.
Real revenue traction and first-time cash flow positivity, but a $40M microcap trading at 57x forward earnings needs proof it can scale HemeScreen without dilution.
Where PRPO is headed
Picture a Precipio that has become the default outsourced cancer diagnostics partner for regional oncology practices and community hospitals that can't justify building their own molecular labs. That is the destination management is aiming at, and the trajectory finally has some signal behind it. Revenue growth of 36% TTM, gross margins pushing 44%, and positive free cash flow of $643K (small, but symbolically enormous for a company that has burned cash for its entire public life) tell you the HemeScreen panel business and the IV-Cell reagent line are finding real customers, not just pilot programs.
Read the full Compass Direction on PRPO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $23.97).
See the full PRPO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Precipio, Inc. (NASDAQ:PRPO) a buy in 2026?
Hold. Precipio, Inc. is a wait-and-watch at today's price, not a fresh buy. Real revenue traction and first-time cash flow positivity, but a $40M microcap trading at 57x forward earnings needs proof it can scale HemeScreen without dilution.
What is PRPO's Compass Score?
Precipio, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for PRPO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PRPO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.